HUP9900275A2 - Pirrolidin- és piperidinszármazékok, eljárás előállításukra és ezeket tartalmazó gyógyásszati készítmények - Google Patents

Pirrolidin- és piperidinszármazékok, eljárás előállításukra és ezeket tartalmazó gyógyásszati készítmények

Info

Publication number
HUP9900275A2
HUP9900275A2 HU9900275A HUP9900275A HUP9900275A2 HU P9900275 A2 HUP9900275 A2 HU P9900275A2 HU 9900275 A HU9900275 A HU 9900275A HU P9900275 A HUP9900275 A HU P9900275A HU P9900275 A2 HUP9900275 A2 HU P9900275A2
Authority
HU
Hungary
Prior art keywords
atom
carbon
low
piperidine derivatives
pyrrolidine
Prior art date
Application number
HU9900275A
Other languages
English (en)
Inventor
Alexander Alanine
Bernd Büttelmann
Marie-Paule Heitz Neidhart
Emmanuel Pinard
René Wyler
Original Assignee
F.Hoffmann-La Roche Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag. filed Critical F.Hoffmann-La Roche Ag.
Publication of HU9900275D0 publication Critical patent/HU9900275D0/hu
Publication of HUP9900275A2 publication Critical patent/HUP9900275A2/hu
Publication of HUP9900275A3 publication Critical patent/HUP9900275A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

A találmány tárgya (I) és (II) általánős képletű pirrőlidin- éspiperidinszármazékők (mely képletben R1 és R2 jelentése egymástól függetlenül hidrőgénatőm, kisszénatőmszámú alkőxi-, hidrőxilcsőpőrt, halőgénatőm, -CONH2 vagy -C(O)O- kis szénatőmszámú alkilcsőpőrt; vagy R1 és R2 együtt -O-CH2-O-csőpőrtőt képez; R3 és R4 jelentése egymástól függetlenül halőgénatőm, kisszénatőmszámú alkőxi-, benzilőxicsőpőrt, halőgénatőm, hidrőxilcsőpőrt,-CONH2 vagy -SCH3 csőpőrt; vagy R3 és R4 együtt -O-CH2-O- csőpőrtőtképez; R5 jelentése hidrőgénatőm vagy kis szénatőmszámú alkilcsőpőrt; X és Y jelentése egymástól függetlenül -CH(OH)-, -(CH2)n-, -C(O)- vagy-CH(kis szénatőmszámú alkőxi)-csőpőrt; és m, n és p értéke 1 vagy 2 és gyógyászatilag alkalmas sóikfelhasználása NMDA receptőr altípűsők túlaktiválása által őkőzőttbetegségek kezelésére és/vagy a megfelelő gyógyászati készítményekelőállítására. ŕ
HU9900275A 1998-02-10 1999-02-08 Pyrrolidine and piperidine derivatives, process for their preparation and pharmaceutical compositions containing them HUP9900275A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98102246 1998-02-10

Publications (3)

Publication Number Publication Date
HU9900275D0 HU9900275D0 (en) 1999-04-28
HUP9900275A2 true HUP9900275A2 (hu) 1999-12-28
HUP9900275A3 HUP9900275A3 (en) 2001-08-28

Family

ID=8231382

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9900275A HUP9900275A3 (en) 1998-02-10 1999-02-08 Pyrrolidine and piperidine derivatives, process for their preparation and pharmaceutical compositions containing them

Country Status (28)

Country Link
US (2) US6015824A (hu)
EP (1) EP0937458B1 (hu)
JP (1) JP3142527B2 (hu)
KR (1) KR100319249B1 (hu)
CN (1) CN1144789C (hu)
AR (1) AR018077A1 (hu)
AT (1) ATE285766T1 (hu)
AU (1) AU748335B2 (hu)
BR (1) BR9900742A (hu)
CA (1) CA2260698A1 (hu)
CZ (1) CZ41099A3 (hu)
DE (1) DE69922858T2 (hu)
DK (1) DK0937458T3 (hu)
ES (1) ES2245808T3 (hu)
HR (1) HRP990042A2 (hu)
HU (1) HUP9900275A3 (hu)
ID (1) ID23456A (hu)
IL (2) IL128389A0 (hu)
MA (1) MA26607A1 (hu)
NO (1) NO990609L (hu)
NZ (1) NZ334081A (hu)
PE (1) PE20000276A1 (hu)
PL (1) PL331336A1 (hu)
PT (1) PT937458E (hu)
SG (1) SG74120A1 (hu)
TR (1) TR199900286A2 (hu)
YU (1) YU5899A (hu)
ZA (1) ZA991038B (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2793245B1 (fr) * 1999-05-05 2002-10-11 Adir Nouveaux composes pyridiniques ou piperidiniques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6369078B1 (en) * 1999-08-31 2002-04-09 J. Phillip Bowen Solenopsin derivatives and analogues as fire ant suppressants
PT1278728E (pt) * 2000-04-20 2004-10-29 Hoffmann La Roche Derivados de pirrolidina e de piperidina e sua utilizacao no tratamento de disturbios neurodegenerativos
JP2004516295A (ja) 2000-12-21 2004-06-03 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー サブタイプ選択的なｎ−メチル−ｄ−アスパラギン酸拮抗薬としてのピペリジン誘導体
MXPA02002749A (es) 2001-03-27 2002-10-28 Warner Lambert Co Derivados de ciclohexilamina como antagonistas del subtipo selectivo del n-metil-d-aspartato.
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
KR20100135847A (ko) * 2008-03-27 2010-12-27 에보텍 뉴로사이언시즈 게엠베하 Ｎｍｄａ ｎｒ２ｂ―서브타입 선택적 길항제를 사용한 질병 치료 방법
BR112012004333A2 (pt) * 2009-08-27 2015-09-08 Merck Sharp & Dohme composto, composição farmacêutica, e, método para o tratamento ou a prevenção de uma doença ou um distúrbio.
WO2011025690A1 (en) * 2009-08-27 2011-03-03 Merck Sharp & Dohme Corp. Novel pyrrolidine derived beta 3 adrenergic receptor agonists

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941796A (en) * 1970-05-21 1976-03-02 Minnesota Mining And Manufacturing Company α-(Hydroxy and alkoxy substituted)phenyl-α-(2-piperidinyl)-methanols
US4407670A (en) * 1980-02-28 1983-10-04 National Research Development Corporation Biocidal compounds and compositions
US4342692A (en) * 1980-10-20 1982-08-03 Usv Pharmaceutical Corporation Pyrrolidines
DK328382A (da) * 1981-07-22 1983-01-23 Syntex Inc Fremgangsmaade til fremstilling af antihypertensive midler
IL70752A0 (en) * 1983-01-24 1984-06-29 Syntex Inc (+-)2-(3,4-methylenedioxyphenethyl)-5-(3-carbamoyl-alpha,4-dihydroxybenzyl)pyrrolidines and salts thereof,their preparation and pharmaceutical compositions containing them
AU2369984A (en) * 1983-01-24 1984-07-26 Syntex (U.S.A.) Inc. Pyridine derivatives
US4569941A (en) * 1983-03-21 1986-02-11 Usv Pharmaceutical Corp. Method of using phenyl-alkylene-2-pyridyl derivatives to increase cardiac contractility in a mammal
US4548951A (en) * 1983-04-21 1985-10-22 Syntex (U.S.A.) Inc. Hypotensive benzoxathiole pyrrolidines
US4558066A (en) * 1984-05-17 1985-12-10 Syntex (U.S.A.) Inc. Treatment and prevention of ocular hypertension
US4632929A (en) * 1985-01-17 1986-12-30 Usv Pharmaceutical Corp. Method of hypertensive treatment using phenyl-alkylene-2-pyridyl derivatives

Also Published As

Publication number Publication date
NZ334081A (en) 2000-07-28
MA26607A1 (fr) 2004-12-20
JP3142527B2 (ja) 2001-03-07
DK0937458T3 (da) 2005-05-17
PL331336A1 (en) 1999-08-16
ZA991038B (en) 1999-08-10
NO990609D0 (no) 1999-02-09
ID23456A (id) 2000-04-27
CN1232025A (zh) 1999-10-20
YU5899A (sh) 2001-07-10
HU9900275D0 (en) 1999-04-28
DE69922858T2 (de) 2006-04-13
EP0937458B1 (en) 2004-12-29
HUP9900275A3 (en) 2001-08-28
ATE285766T1 (de) 2005-01-15
US6153624A (en) 2000-11-28
IL128389A0 (en) 2000-01-31
ES2245808T3 (es) 2006-01-16
CZ41099A3 (cs) 1999-09-15
JP2000063384A (ja) 2000-02-29
DE69922858D1 (de) 2005-02-03
PE20000276A1 (es) 2000-04-18
AR018077A1 (es) 2001-10-31
IL144456A0 (en) 2002-05-23
PT937458E (pt) 2005-04-29
KR19990072459A (ko) 1999-09-27
EP0937458A2 (en) 1999-08-25
NO990609L (no) 1999-08-11
AU748335B2 (en) 2002-05-30
CN1144789C (zh) 2004-04-07
CA2260698A1 (en) 1999-08-10
BR9900742A (pt) 2000-05-09
EP0937458A3 (en) 2001-05-23
AU1635499A (en) 1999-08-26
TR199900286A3 (tr) 1999-09-21
KR100319249B1 (ko) 2002-01-05
HRP990042A2 (en) 2000-02-29
US6015824A (en) 2000-01-18
TR199900286A2 (xx) 1999-09-21
SG74120A1 (en) 2000-07-18

Similar Documents

Publication Publication Date Title
SE9904738D0 (sv) Novel compounds
HUP0105437A2 (hu) Új malonsavszármazékok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények
MX9604020A (es) Arilalquildiazinonas.
HUP0401253A2 (hu) Dolastatin 10 származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
TR200001973T2 (tr) 11 ß-halojen-7alfa-ile ikame edilmiş-estratrienler, bu 11ß-halojen-7alfa-ile ikame edilmiş-estratrienleri içeren farmasötik terkiplerin üretimi için yöntem ve ilaç üretiminde kullanımları.
HUP0100305A2 (hu) PDE IV inhibitor aktivitású purinszármazékok, azokat tartalmazó gyógyszerkészítmények és eljárás előállításukra
HUT53106A (en) Process for producing new thienotriazolo-1,4-diazepine derivatives and pharmaceutical compositions comprising such compounds
ES2187261A1 (es) Compuestos de eteres y amidas y su preparacion, como agentes anti-diabeticos.
ES487677A1 (es) Procedimiento para la preparacion de derivados de aril-ete- res
ES2087038A1 (es) Nuevas piperidinas con actividad antagonista del paf.
HUP9900275A2 (hu) Pirrolidin- és piperidinszármazékok, eljárás előállításukra és ezeket tartalmazó gyógyásszati készítmények
HUP9802408A2 (hu) Naftil- és dihidronaftilszármazékok, és ezeket a vegyületeket tartalmazó gyógyszerkészítmények
AR002016A1 (es) Derivados de 3-fenilisoquinoleina-1-(2h)-ona, procedimiento para su preparacion y medicamento y composicion farmaceutica que los contienen.
EP0398720A3 (en) Piperazine derivatives
HUP0003577A2 (hu) Tetrahidro-gamma-karbolinok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
HUP0003624A2 (hu) 1,2,3,4-Tetrahidro-benzofuro[3,2-c]piridin-származékok, az ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
BG101220A (en) N-substituted 3-azabicyclo (93.2.0) heptane derivatives,their preparation and use
ATE239711T1 (de) Neue allythiopyridazinderivate und verfahren zu ihrer herstellung
MD522G2 (ro) Noi derivaţi de piperidinii tioindol, procedeu de preparare a lor, compoziţii farmaceutice care le conţin, utilizare a lor ca analgezice
IL66804A0 (en) 2-amino-1,2,3,4-tetrahydronaphthalene derivatives,their preparation and pharmaceutical compositions containing them
HUP0202647A2 (hu) Új arilalkanoilszármazékok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények
HUP0301548A2 (hu) NMDA receptor ligandok előgyógyszerei, eljárás az előállításukra és alkalmazásuk gyógyszerkészítmények előállítására
SE8603589L (sv) Metylendioxifenantren- och stilbenderivat
HUP0003159A2 (hu) N-monoszubsztituált-3-oxo-4-aza-5alfa-androszt-1-én-17béta-karboxamidok alkalmazása gyógyászati készítmények előállítására
HU9203928D0 (en) 6-sulfonyl-substituted 3-hydroxi-chromane derivatives and pharmaceutical preparatives containing them